Zaleplon - Drug Monograph

Introduction

Zaleplon is a non-benzodiazepine hypnotic ("Z-drug") used primarily for the short-term treatment of insomnia characterized by difficulty falling asleep. It is notable for its very short half-life, which makes it particularly suited for sleep-onset rather than sleep-maintenance insomnia. Because of its selectivity at the benzodiazepine recognition site and rapid elimination, zaleplon has a comparatively favorable profile for next-day sedation, though it shares the core class risks of complex sleep behaviors, dependence, and withdrawal with other sedative-hypnotics.

Drug Class and Overview

• Class: Sedative-hypnotic; non-benzodiazepine benzodiazepine receptor agonist ("Z-drug").
• Related agents: Zolpidem, eszopiclone (also "Z-drugs"); pharmacologically related to benzodiazepines (e.g., triazolam, temazepam) but structurally distinct.
• Key distinguishing features:
• Ultra-short elimination half-life (≈1 hour).
• Indicated for sleep-onset insomnia; can be dosed as needed, including after middle-of-the-night awakening if ≥4 hours of sleep time remain (per FDA labeling).
• Lower risk of next-day sedation compared with longer-acting agents, but not risk-free.

Mechanism of Action

Zaleplon binds selectively to the benzodiazepine recognition site on the GABA_A receptor complex (primarily α1 subunit–containing subtypes). This binding enhances the affinity of GABA for its receptor, increasing chloride ion conductance, neuronal hyperpolarization, and inhibition of CNS arousal pathways. The α1-subunit–selective binding is thought to account for its predominantly hypnotic (rather than anxiolytic, muscle relaxant, or anticonvulsant) activity.

Indications

• Short-term treatment of insomnia characterized by difficulty initiating sleep (sleep-onset insomnia).
• Has been studied (off-label in some jurisdictions) for middle-of-the-night awakening administration when ≥4 hours remain for sleep; FDA labeling allows this specific use.

Dosage and Administration

• Adults: 10 mg orally at bedtime or after going to bed if difficulty falling asleep; may be used after middle-of-the-night awakening if ≥4 hours of sleep time remain. Maximum recommended single dose: 20 mg; maximum daily dose generally 20 mg.
• Elderly / Debilitated: Start at 5 mg; usual dose 5–10 mg (increased sensitivity).
• Hepatic impairment (mild to moderate): 5 mg (clearance reduced).
• Severe hepatic impairment: Not recommended (per labeling).
• Renal impairment: No dose adjustment typically required; drug is predominantly hepatically metabolized.
• Pediatric patients: Not indicated; safety and effectiveness not established in children.
• Pregnancy / Lactation: Generally not recommended; use only if potential benefit justifies potential risk. Zaleplon is excreted in breast milk.

Pharmacokinetics

• Absorption: Rapidly absorbed; peak plasma concentration (Tmax) ≈1 hour. High-fat meals delay absorption.
• Distribution: Moderately lipophilic; volume of distribution ≈1.4 L/kg. Protein binding ≈45–60%.
• Metabolism: Primarily hepatic via aldehyde oxidase (major pathway), with minor contributions from CYP3A4. Forms inactive metabolites (e.g., 5-oxo-zaleplon and desethylzaleplon).
• Elimination: Renal excretion of inactive metabolites; <1% excreted as unchanged drug.
• Half-life: ≈1 hour (ultra-short), which underpins its use for sleep-onset symptoms with minimal next-day effect.

Contraindications

• Hypersensitivity to zaleplon or any component of the formulation.

Warnings and Precautions

• Complex sleep behaviors (e.g., sleepwalking, sleep-driving, sleep-eating) — potentially dangerous, often with amnesia; discontinue if occurs.
• CNS depression / next-day impairment — even with short half-life, impairment can occur, especially with higher doses, concomitant CNS depressants, or inadequate sleep time.
• Abuse, dependence, and withdrawal — tolerance, physical dependence, and withdrawal symptoms can develop, particularly with prolonged use or high doses; avoid in patients with substance use disorder history.
• Severe hepatic impairment — use not recommended.
• Depression / suicidality — caution in patients with depression; sedative-hypnotics may unmask or worsen depressive symptoms.
• Concomitant alcohol or CNS depressants — additive CNS depression; avoid.

Drug Interactions

• CNS depressants (alcohol, opioids, benzodiazepines, antipsychotics, antihistamines, muscle relaxants): Additive sedation and respiratory depression; avoid or minimize co-administration.
• CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort): May decrease zaleplon exposure and efficacy (minor metabolic pathway; effect generally modest but monitor).
• CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin): Mild to moderate increase in zaleplon exposure; clinical effect usually small but monitor for excess sedation.
• Cimetidine (aldehyde oxidase inhibitor): Modestly increases zaleplon concentrations; caution.
• Diphenhydramine and other anticholinergic antihistamines: Additive sedation and psychomotor impairment.

Adverse Effects

• Common: Headache, dizziness, drowsiness, nausea, abdominal pain, weakness, dry mouth, dyspepsia.
• Less common but clinically important: Amnesia (especially if awakened shortly after dosing), complex sleep-related behaviors, paradoxical reactions (agitation, anxiety, hallucinations), next-day somnolence or impaired psychomotor function.
• Rare but serious: Anaphylaxis / angioedema, severe withdrawal reactions after high-dose or prolonged use, dependence with continued use beyond recommended duration.

Monitoring Parameters

• Sleep pattern, sleep-onset latency, and total sleep time.
• Daytime alertness and cognitive / psychomotor function.
• Mood changes, especially emergence of depression or suicidal ideation.
• Signs of tolerance, dependence, or misuse (request for refills, escalating doses).
• Hepatic function in patients with known or suspected hepatic impairment.
• Adverse effects such as morning sedation, falls (particularly in elderly), and complex sleep behaviors.

Patient Education

• Take exactly as prescribed, immediately before bedtime or after going to bed; only when you can remain in bed for at least 4 hours.
• Do not take with or shortly after a high-fat meal, which delays onset.
• Avoid alcohol and other sedatives; they increase CNS depression.
• Do not drive or operate machinery if you feel drowsy the next day.
• Report unusual sleep behaviors (sleepwalking, sleep-driving, sleep-eating), memory problems, or daytime impairment.
• This medication is intended for short-term use; do not increase the dose or use longer than prescribed.
• Inform your prescriber if you have a history of substance use disorder, depression, or liver problems.
• If pregnant, planning pregnancy, or breastfeeding, discuss risks with your provider.

Clinical Pearls

• Zaleplon's ultra-short half-life (~1 hour) makes it the prototypical "sleep-onset only" hypnotic; it is rarely associated with next-day sedation when used as labeled.
• It can be dosed after a middle-of-the-night awakening as long as ≥4 hours of sleep time remain — a unique feature among the Z-drugs.
• Zaleplon is one of the few hypnotics metabolized primarily via aldehyde oxidase, not CYP enzymes, which is why CYP interactions are clinically modest.
• Despite its selectivity, zaleplon carries the same class warnings as benzodiazepines and other Z-drugs regarding complex sleep behaviors, dependence, and withdrawal — always counsel patients.
• In older adults, "start low" (5 mg) is essential due to increased sensitivity and elevated fall risk with any sedative-hypnotic.
• For chronic insomnia, cognitive behavioral therapy for insomnia (CBT-I) is first-line; pharmacotherapy (including zaleplon) is best used short-term or intermittently while CBT-I is initiated.

References

1. U.S. Food and Drug Administration. Sonata (zaleplon) Capsules Prescribing Information.
2. National Institutes of Health, U.S. National Library of Medicine. Zaleplon – Drug Information (DailyMed/LactMed-style reference).
3. American Academy of Sleep Medicine. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults.
4. Wilt, T.J., et al. Pharmacologic Treatment of Insomnia Disorder: An Evidence Report. U.S. Department of Veterans Affairs / AHRQ Comparative Effectiveness Review.
5. World Health Organization. WHO Model List of Essential Medicines – sedative/hypnotic agents (general reference framework).
6. Brunton, L.L., & Knollmann, B.C. (eds.). Goodman & Gilman's The Pharmacological Basis of Therapeutics. (Sedative-hypnotic drug class chapter; standard pharmacology textbook.)
7. Katzung, B.G., & Vanderah, T.W. (eds.). Basic & Clinical Pharmacology. (Hypnotics/sedatives chapter; standard pharmacology textbook.)
8. Lexicomp Online. Zaleplon Drug Monograph. (Standard clinical drug reference.)
9. American Psychiatric Association. Practice Guidelines for the Treatment of Patients with Substance Use Disorders (general principles relevant to sedative-hypnotic dependence).
10. European Medicines Agency. Assessment Report on Zaleplon-containing Medicinal Products (regulatory review document).